Safety and efficacy of autologous hematopoietic stem-cell transplantation following natalizumab discontinuation in aggressive multiple sclerosis.

Alice MariottiniC InnocentiB ForciE MagnaniC MechiA BarilaroR NistriA FaniR SaccardiL MassacesiA M Repice

Published in: European journal of neurology (2018)

These data suggest that an aggressive therapy should be established after NTZ with the shortest possible wash-out period. aHSCT after 6 months from NTZ withdrawal appears to be safe.

Keyphrases

multiple sclerosis
white matter
electronic health record
cell therapy
acute myeloid leukemia
bone marrow
platelet rich plasma
data analysis
replacement therapy
smoking cessation